NFL Greats Tackle Prostate Cancer Myths in Super Bowl Health Blitz

EAST HANOVER, N.J. – January 29, 2026 – In a bold move set to capture the attention of over 120 million viewers, pharmaceutical giant Novartis is teaming up with a roster of NFL legends for a national health campaign that will debut during Super Bowl LX. The initiative, titled "Relax, it's a blood test," aims to dismantle a pervasive and dangerous fear surrounding prostate cancer screening, leveraging the massive cultural platform of professional football to save lives.

At the heart of the campaign is a simple, powerful message: the first step in screening for prostate cancer is not the invasive exam many men fear, but a straightforward blood test. The effort features a lineup of gridiron heroes, including Super Bowl-winning coach Bruce Arians, legendary tight ends Rob Gronkowski, George Kittle, Tony Gonzalez, and Greg Olsen, among others. Their goal is to cut through the stigma and misinformation that prevent millions of men from seeking a potentially life-saving diagnosis.

The Super Bowl Playbook for Public Health

The decision to launch during the Super Bowl on February 8 is a calculated one. The event is a cultural touchstone, and its advertising slots are the most coveted in television. By placing a public health message in this arena, Novartis and its partners are betting they can normalize conversations about men's health in a way few other venues allow.

"By teaming up with the NFL and these celebrated players, we're empowering men nationwide to take the first step: a simple blood test," said Victor Bultó, President of US Novartis, in a statement. The strategy leans on the well-documented power of celebrity influence. History shows that when trusted figures speak out, especially on sensitive topics, the public listens. Athletes, often seen as paragons of strength and resilience, can be particularly effective messengers for health issues, helping to reframe proactive healthcare as a sign of strength, not weakness.

This is especially true for the campaign's target demographic. The message is designed to resonate in living rooms, sports bars, and social gatherings where the game is watched, encouraging men to turn to their friends and family and start a conversation that could lead them to a doctor's office.

Beyond the Pill: A New Pharmaceutical Strategy

While the campaign's public-facing goal is purely educational, it also signals an evolution in the role of pharmaceutical companies in the healthcare ecosystem. Novartis is a major player in the oncology space, with advanced treatments for diagnosed prostate cancer, such as its targeted radioligand therapy, Pluvicto. By funding a large-scale awareness campaign that promotes screening, the company is engaging in a long-term strategy of market shaping.

Increasing the number of men who get screened will inevitably lead to more early-stage diagnoses. While early detection dramatically improves a patient's prognosis—the five-year survival rate for localized prostate cancer is over 99%—it also expands the pool of patients who may eventually need therapeutic interventions. This positions the campaign as a dual-purpose initiative: a significant act of corporate social responsibility that also aligns with the company's long-term business interests in oncology. The collaboration with esteemed advocacy groups like the American Cancer Society and ZERO Prostate Cancer lends further credibility to the public health mission, grounding the corporate initiative in the established expertise of the patient support community.

"Expanding access to cancer screening, especially in communities where limited resources and persistent misconceptions have hindered life-saving education and care, is essential to changing outcomes," noted Shane Jacobson, CEO of the American Cancer Society.

The Simple Truth That Could Save Millions

The core of the campaign is its direct assault on a critical misconception. Statistics show that one in eight American men will be diagnosed with prostate cancer in their lifetime, making it the most common non-skin cancer among them. It is also the second leading cause of cancer death. Yet, a staggering 60% of men mistakenly believe that screening begins and ends with an uncomfortable digital rectal exam (DRE).

This fear and misunderstanding create a formidable barrier to action. An estimated 40.3 million men in the U.S. who should be discussing screening with their doctors have never had a prostate-specific antigen (PSA) blood test—the simple, initial screening tool.

The campaign's name, "Relax, it's a blood test," confronts this anxiety head-on. For former NFL head coach Bruce Arians, the message is deeply personal. "I was diagnosed with prostate cancer in 2007, and early detection saved my life," Arians shared. "I hear men all the time say they're hesitant to get screened because of what they think it involves. There is no need to avoid it if you talk to a doctor and learn your risk. You can relax, it's a blood test."

Tackling Disparities and Reaching the Vulnerable

Beyond its broad appeal, the initiative carries a specific and urgent focus on addressing stark health disparities. Black men are at a significantly higher risk, facing a 70% greater chance of being diagnosed with prostate cancer and being more than twice as likely to die from it compared to white men. These disparities are fueled by a complex mix of genetic factors, socioeconomic barriers, and historical mistrust in the medical system.

To combat this, Novartis and its partners are planning targeted outreach. The campaign's online hub, RelaxItsABloodTest.com, will provide risk assessment tools and tailored information. Furthermore, planned on-site screening events with NFL teams and activations at the Super Bowl Experience aim to bring resources directly into communities, lowering access barriers. By working with organizations that have deep roots in these communities, the campaign hopes to deliver a culturally competent message that fosters trust and encourages action where it is most desperately needed. The ultimate goal is to ensure that the life-saving message of early detection reaches every man, regardless of his background or zip code.